Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?Zacks Investment Research • 09/10/26
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic SclerosisGlobeNewsWire • 09/03/26
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 CongressGlobeNewsWire • 09/02/26
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare ConferenceGlobeNewsWire • 09/01/26
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Zacks Investment Research • 08/27/26
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?Zacks Investment Research • 08/17/26
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue PathZacks Investment Research • 08/13/26
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins FollowSeeking Alpha • 08/13/26
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/12/26
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?Zacks Investment Research • 07/31/26
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026GlobeNewsWire • 07/29/26
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?Zacks Investment Research • 07/24/26